Anesthesia for patients with malignant hyperthermia and those at risk
case report
DOI:
https://doi.org/10.47456/rbps.v26i1.41535Keywords:
Malignant hyperthermia, Halogenated, Succinylcholine, Pre-anesthetic preparation, Perioperative environmentAbstract
Introduction: Malignant hyperthermia (MH) is a pharmacogenetic clinical syndrome that, in its classic form, occurs during anesthesia with the use of drugs that trigger the MH crisis, such as halogenated drugs or the depolarizing neuromuscular blocker - succinylcholine. It was defined as an autosomal dominant inheritance, with more than 210 mutations in the ryanodine receptor (RYR1) in skeletal muscle. Case report: With the present case report and current bibliographic review, the objective is to describe the safe anesthetic technique used in a patient susceptible to MH and to make some considerations. The procedure was performed at the Hospital Universitário Cassiano Antônio Moraes (HUCAM/UFES), with adequate preparation of the perioperative environment. Conclusion: This article serves as a foundation for preparing a safer and more suitable environment for anesthetic management of patients susceptible to MH or with a confirmed diagnosis.
Downloads
References
Cangiani LM, Carmona MJC, Ferez D, Bastos CO, Duarte LTD, Cangiani LH, Falcão LFR, Tardelli MA, Rodrigues RC. Tratado de anestesiologia. SAESP: Editora dos Editores; 2021 [cited 2023 May 31]. doi: 10.51864/9786586098327.
Miller RD, Cohen NH, Eriksson LI, Fleisher LA, Kronish JPW, Young WL. Miller Anestesia. 8. ed. Rio de Janeiro: Elsevier Editora Conhecimento sem Fronteiras; 2015.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare, 2015 ago;10(1). [internet]. [cited 2023 May 31]. doi: 10.1186/s13023-015-0310-1.
Gupta PK, Bilmen JG, Hopkins PM. Anesthetic management of a known or suspected malignant hyperthermia susceptible patient. BJA Educ, 2021 jun; 21(6):218-24. [internet]. [cited 2023 May 31]. doi: 10.1016/j.bjae.2021.01.003.
Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology, 2018 jan;128(1):159-67 [internet]. [cited 2023 May 31]. doi: 10.1097/aln.0000000000001877.
CEDHIMA. Centro de Estudo, Diagnóstico e Investigação de Hipertermia Maligna [internet]. [cited 2023 May 31]. http://cedhima.sites.unifesp.br/site/.
Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, Müller CR, Urwyler A. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth, 2015 out; 115(4):531-9 [internet]. [cited 2023 May 31]. doi: 10.1093/bja/aev225.
Glahn KP, Bendixen D, Girard T, Hopkins PM, Johannsen S, Rüffert H, Snoeck MM, Urwyler A. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth, 2020 ago;125(2):133-40 [internet]. [cited 2023 May 31]. doi: 10.1016/j.bja.2020.04.089.
MHAUS. Preparing the Anesthesia Machine for MHS Patients [internet]. Mhaus.org. 2016. [cited 2023 May 31]. https://www.mhaus.org/healthcare-professionals/be-prepared/preparing-the- anesthesia-machine/.
Silva WV, Ferez D, Mattos SLL, Nunes RR, Lima LHN, Lima RM. SAVA - Suporte avançado de vida em anestesia. 2. ed. Rio de Janeiro: Sociedade Brasileira de Anestesiologia; 2018. 434 p.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
